Silence Therapeutics Plc American Depository Share (SLN) Stock
Fundamentals
Recent news

Silence Therapeutics to Participate in Three September Investor Conferences
Silence Therapeutics to Participate in Three September Investor Conferences
SLN

Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional ADSs
Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional ADSs
SLN

Wall Street Analysts Predict a 140.06% Upside in Silence Therapeutics (SLN): Here's What You Should Know
Wall Street Analysts Predict a 140.06% Upside in Silence Therapeutics (SLN): Here's What You Should Know
SLN

Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering
Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering
SLN
Technicals
Analyst Ratings
Financials
Performance
No data available
Debt & Balance Sheet
No data available
Revenue to Profit
No data available
Earnings
No data available
% positive news of 10 articles
published over the past 14 days
Latest news

Silence Therapeutics to Participate in Three September Investor Conferences
Silence Therapeutics to Participate in Three September Investor Conferences
SLN

Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional ADSs
Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional ADSs
SLN

Wall Street Analysts Predict a 140.06% Upside in Silence Therapeutics (SLN): Here's What You Should Know
Wall Street Analysts Predict a 140.06% Upside in Silence Therapeutics (SLN): Here's What You Should Know
SLN

Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering
Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering
SLN

Silence Therapeutics' Divesiran Hits Phase II Goal, Sets Up Phase III PV Trial
Silence Therapeutics' Divesiran Hits Phase II Goal, Sets Up Phase III PV Trial
SLN

Silence Therapeutics Announces Proposed Public Offering of $150 Million of American Depositary Shares
Silence Therapeutics Announces Proposed Public Offering of $150 Million of American Depositary Shares
SLN

Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile
Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile
SLN

Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results
Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results
SLN

Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera
Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera
SLN

SLN Stock Skyrockets 107% in Six Months: Here's What You Need to Know
SLN Stock Skyrockets 107% in Six Months: Here's What You Need to Know
SLN
About Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Iain Gladstone Ross B.Sc., BSc (Hons), C.DIR, CH.D | Interim CEO & Chairman of the Board | 1954 |
| Ms. Rhonda L. Hellums | Executive VP, CFO, Secretary & Executive Director | 1971 |
| Dr. Steven J. Romano M.D. | Executive VP and Chief Research & Development Officer | 1959 |
| Dr. Marie Wikstrom Lindholm Ph.D. | Chief Scientific Officer | — |
| Ms. Gem Gokmen Hopkins | Head of IR & Corporate Communications | — |
| Mr. Jaimin B. Shah | SVP & General Counsel | — |
| Mr. J.P. Gabriel | Chief Technical Operations Officer | — |
| Mr. Curtis Rambaran M.D. | Chief Medical Officer | — |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Solvency
Technicals
What the experts say
1 Wall Street Analyst Ratings
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +19.9 | -0.1 | +26.7 | -24.2 |



